Small extracellular vesicles containing miR-192/215 mediate hypoxia-induced cancer-associated fibroblast development in head and neck squamous cell carcinoma

The mechanisms underlying the hypoxic most cancers cell-mediated differentiation of cancer-associated fibroblasts (CAFs) haven’t been elucidated but. The current examine confirmed that the hypoxic head and neck squamous cell carcinoma (HNSCC) cells promoted CAF-like differentiation via secreting TGF-β and small extracellular vesicles (sEVs) that include enhanced ranges of miR-192/215 household miRNAs. Caveolin-1 (CAV1), which is a goal gene of miR-192/215, inhibited the TGF-β/SMAD signaling and promoted CAF-like differentiation of the fibroblasts. Restoring the degrees of CAV1 inhibited the hypoxic sEV- and TGF-β-induced CAF-like differentiation.

The enhanced ranges of miR-192/215 encapsulated in the HNSCC tissue-derived sEVs (however not serum-derived sEVs) indicated hypoxic and aggressive most cancers stroma. miR-215 in the tumor tissue-derived sEVs (however not circulating sEVs) was correlated with poor general survival of sufferers with HNSCC. This examine demonstrated that sEVs perform as a “courier” to ship miRNAs from the most cancers cells to the fibroblasts, which promotes the reworking of the hypoxic tumor microenvironment, and that most cancers tissue-derived sEV may doubtlessly function a supply of biomarker.

The intention of this examine was to analyze utilizing myogenic differentiation of adipose stem cells for the remedy of feminine pelvic ground dysfunction (PFD) and aimed to additional examine the influences of microRNA-124-3p (miR-124-3p) in the method of myogenic differentiation of adipose-derived stem cells (ADSCs) via concentrating on Caveolin-1 (Cav1) throughout PFD in Sprague Dawley (SD) rats.

Comprehensive evaluation of lncRNA-associated ceRNA community reveals the novel potential of lncRNA, miRNA and mRNA biomarkers in human rectosigmoid junction most cancers

Although accumulating proof has confirmed the potential organic capabilities of lengthy non-coding RNAs (lncRNAs) as aggressive endogenous RNAs (ceRNAs) in colorectal tumorigenesis and development, few research have targeted on rectosigmoid junction most cancers. In the current examine, a complete evaluation was carried out to discover lncRNA-mediated ceRNA implications and their potential worth for prognosis. lncRNA, microRNA (miR/miRNA) and mRNA expression profiles had been downloaded from The Cancer Genome Atlas database.

Subsequently, a lncRNA-miRNA-mRNA regulatory community was constructed to guage the capabilities of those differentially expressed genes on general survival (OS) for rectosigmoid junction most cancers. As a outcome, a rectosigmoid junction cancer-specific ceRNA community was efficiently constructed with 7 differentially expressed (DE)lncRNAs, 16 DEmiRNAs and 71 DEmRNAs. Among the community, one DElncRNA (small nucleolar RNA host gene 20) and three mRNAs (sodium- and chloride-dependent taurine transporter, fibroblast progress issue 13 and tubulin polyglutamylase TTLL7) had been considerably related to OS (P<0.05).

Additionally, two lncRNAs (KCNQ1OT1 and MIR17HG) interacted with many of the DEmiRNAs. Notably, two top-ranked miRNAs (hsa-miR-374a-5p and hsa-miR-374b-5p) related networks had been recognized to be markedly related to the pathogenesis. Furthermore, 4 DEmRNAs (caveolin-1, MET, filamin-A and AKT3) had been enriched in the Kyoto Encylopedia of Gene and Genomes pathway evaluation, in addition to being included in the ceRNA community. In abstract, the current outcomes revealed {that a} particular lncRNA-miRNA-mRNA community was related to rectosigmoid junction most cancers, offering a number of molecules that could be used as novel prognostic biomarkers and therapeutic targets.

Small extracellular vesicles containing miR-192/215 mediate hypoxia-induced cancer-associated fibroblast development in head and neck squamous cell carcinoma

Endocytic pathway inhibition attenuates extracellular vesicle-induced discount of chemosensitivity to bortezomib in a number of myeloma cells

Extracellular vesicles (EVs), together with exosomes and microvesicles, derived from bone marrow stromal cells (BMSCs) have been demonstrated as key components in the development and drug resistance of a number of myeloma (MM). EV uptake entails a wide range of mechanisms which largely depend upon the vesicle origin and recipient cell kind. The intention of the current examine was to establish the mechanisms concerned in the uptake of BMSC-derived small EVs (sEVs) by MM cells, and to guage the anti-MM impact of concentrating on this course of.

Human BMSC-derived sEVs had been recognized by transmission electron microscopy, nanoparticle monitoring evaluation, and western blot. The results of chemical inhibitors and shRNA-mediated knockdown of endocytosis-associated genes on sEV uptake and cell apoptosis had been analyzed by circulation cytometry. The anti-MM impact of blocking sEV uptake was evaluated in vitro and in a xenograft MM mouse mannequin.

sEVs derived from BMSC had been taken up by MM cells in a time- and dose-dependent method, and subsequently promoted MM cell biking and decreased their chemosensitivity to bortezomib. Chemical endocytosis inhibitors concentrating on heparin sulphate proteoglycans, actin, tyrosine kinase, dynamin-2, sodium/proton exchangers, or phosphoinositide 3-kinases considerably decreased MM cell internalization of BMSC-derived sEVs.

Moreover, shRNA-mediated knockdown of endocytosis-associated proteins, together with caveolin-1, flotillin-1, clathrin heavy chain, and dynamin-2 in MM cells suppressed sEV uptake. Furthermore, an endocytosis inhibitor concentrating on dynamin-2 preferentially suppressed the uptake of sEV by major MM cells ex vivo and enhanced the anti-MM results of bortezomib in vitro and in a mouse mannequin. Clathrin- and caveolin-dependent endocytosis and macropinocytosis are the predominant routes of sEV-mediated communication between BMSCs and MM cells, and inhibiting endocytosis attenuates sEV-induced discount of chemosensitivity to bortezomib, and thus enhances its anti-MM properties.

Caveolin- 1 Antibody

ABF0126 100 ug
EUR 438

Caveolin 1 Antibody

ABF5372 100 ug
EUR 438

Caveolin- 1 Antibody

ABF6386 100 ug
EUR 438

Caveolin-1 Antibody

AF0126 200ul
EUR 304
Description: Caveolin-1 antibody detects endogenous levels of total Caveolin-1.

anti-Caveolin 1

YF-PA10691 100 ug
EUR 403
Description: Rabbit polyclonal to Caveolin 1

Caveolin-1 Antibody

A1010-50
EUR 403

Caveolin 1 antibody

20R-1949 50 ug
EUR 281
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin 1 antibody

20R-2291 50 ug
EUR 281
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin-1 Peptide

45-027P 0.1 mg
EUR 338
Description: (IN) Caveolin-1 Peptide

Caveolin-1 Peptide

8219P 0.05 mg
EUR 164.75
Description: Caveolin-1 Peptide

Caveolin 1 antibody

70R-31113 100 ug
EUR 327
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin 1 antibody

70R-35767 100 ug
EUR 327
Description: Rabbit polyclonal Caveolin 1 antibody

Caveolin 1 antibody

70R-49479 100 ul
EUR 244
Description: Purified Polyclonal Caveolin 1 antibody

Caveolin 1 antibody

70R-49480 100 ul
EUR 244
Description: Purified Polyclonal Caveolin 1 antibody

Caveolin-1 Antibody

8219-002mg 0.02 mg
EUR 171.82
Description: Caveolin-1 Antibody: Caveolin-1 is a scaffolding protein that is the main component of the caveolae plasma membranes found in most cell types (1). The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression (2). The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 mitogen-activated kinase cascade (3). Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy (4).

Caveolin-1 Antibody

8219-01mg 0.1 mg
EUR 436.42
Description: Caveolin-1 Antibody: Caveolin-1 is a scaffolding protein that is the main component of the caveolae plasma membranes found in most cell types (1). The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression (2). The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 mitogen-activated kinase cascade (3). Mutations in this gene have been associated with Berardinelli-Seip congenital lipodystrophy (4).

Dog Caveolin-1 (CAV1)

1-CSB-YP004571DO
  • EUR 679.00
  • EUR 335.00
  • EUR 2172.00
  • EUR 1051.00
  • EUR 1442.00
  • EUR 435.00
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Dog Caveolin-1(CAV1) expressed in Yeast

Recombinant Caveolin 1 (CAV1)

4-RPA214Hu01
  • EUR 522.91
  • EUR 243.00
  • EUR 1685.92
  • EUR 628.64
  • EUR 1157.28
  • EUR 413.00
  • EUR 4064.80
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Caveolin 1 expressed in: E.coli

Recombinant Caveolin 1 (CAV1)

4-RPA214Mu01
  • EUR 565.92
  • EUR 254.00
  • EUR 1847.20
  • EUR 682.40
  • EUR 1264.80
  • EUR 442.00
  • EUR 4468.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Mouse Caveolin 1 expressed in: E.coli

Recombinant Caveolin 1 (CAV1)

4-RPA214Ra01
  • EUR 637.60
  • EUR 274.00
  • EUR 2116.00
  • EUR 772.00
  • EUR 1444.00
  • EUR 490.00
  • EUR 5140.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Rat Caveolin 1 expressed in: E.coli

Caveolin-1 Polyclonal Antibody

ES1872-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Caveolin-1 Polyclonal Antibody

ES1872-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA

Caveolin-1 Polyclonal Antibody

ES1873-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Caveolin-1 Polyclonal Antibody

ES1873-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against Caveolin-1 from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, IHC, IF, WB, ELISA

Polyclonal Caveolin-1 Antibody

APG02445G 0.05ml
EUR 528
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Caveolin-1 . This antibody is tested and proven to work in the following applications:

Polyclonal Caveolin-1 Antibody

APG02446G 0.1ml
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Caveolin-1 . This antibody is tested and proven to work in the following applications:

Caveolin-1 Polyclonal Antibody

ABP50873-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14

Caveolin-1 Polyclonal Antibody

ABP50873-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14

Caveolin-1 Polyclonal Antibody

ABP50873-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Caveolin-1 around the non-phosphorylation site of Y14

Caveolin-1 Polyclonal Antibody

ABP50874-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180

Caveolin-1 Polyclonal Antibody

ABP50874-01ml 0.1ml
EUR 289
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180

Caveolin-1 Polyclonal Antibody

ABP50874-02ml 0.2ml
EUR 414
Description: A polyclonal antibody for detection of Caveolin-1 from Human, Mouse, Rat. This Caveolin-1 antibody is for WB, IHC-P, IF, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human Caveolin-1 at AA range: 100-180

Caveolin 1 (CAV1) Antibody

20-abx116788
  • EUR 732.00
  • EUR 398.00
  • 150 ul
  • 50 ul

Caveolin 1 (CAV1) Antibody

abx122002-100ug 100 ug
EUR 391

Caveolin 1 (CAV1) Antibody

20-abx125305
  • EUR 495.00
  • EUR 704.00
  • EUR 356.00
  • 100 ul
  • 200 ul
  • 50 ul

Caveolin 1 (CAV1) Antibody

20-abx100474
  • EUR 398.00
  • EUR 133.00
  • EUR 1107.00
  • EUR 537.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 (CAV1) Antibody

20-abx100475
  • EUR 411.00
  • EUR 133.00
  • EUR 1135.00
  • EUR 551.00
  • EUR 314.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 (CAV1) Antibody

20-abx100476
  • EUR 425.00
  • EUR 133.00
  • EUR 1177.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 Blocking Peptide

20-abx062354
  • EUR 272.00
  • EUR 411.00
  • 1 mg
  • 5 mg

Caveolin 1 Blocking Peptide

20-abx062355
  • EUR 272.00
  • EUR 411.00
  • 1 mg
  • 5 mg

Caveolin-1 (CAV1) Antibody

20-abx137365
  • EUR 704.00
  • EUR 328.00
  • EUR 230.00
  • 100 ug
  • 20 ug
  • 5 ug

Caveolin 1 (CAV1) Antibody

20-abx000539
  • EUR 411.00
  • EUR 592.00
  • EUR 314.00
  • 100 ul
  • 200 ul
  • 50 ul

Caveolin 1 (CAV1) Antibody

20-abx009491
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Caveolin 1 (CAV1) Antibody

20-abx009492
  • EUR 300.00
  • EUR 439.00
  • EUR 189.00
  • 100 ul
  • 200 ul
  • 30 ul

Caveolin 1 (pT14) Antibody

20-abx009682
  • EUR 314.00
  • EUR 467.00
  • EUR 203.00
  • 100 ul
  • 200 ul
  • 30 ul

Caveolin 1 (pY14) Antibody

abx010493-100ug 100 ug
EUR 439

Caveolin 1 (CAV1) Antibody

20-abx013031
  • EUR 314.00
  • EUR 98.00
  • EUR 398.00
  • EUR 495.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Caveolin 1 (CAV1) Antibody

abx019037-100ug 100 ug
EUR 342

Caveolin-1 Rabbit mAb

A19006-100ul 100 ul
EUR 410

Caveolin-1 Rabbit mAb

A19006-200ul 200 ul
EUR 571

Caveolin-1 Rabbit mAb

A19006-20ul 20 ul
EUR 221

Caveolin-1 Rabbit mAb

A19006-50ul 50 ul
EUR 287

Caveolin 1 (CAV1) Antibody

abx431142-200ul 200 ul
EUR 384

Caveolin 1 Antibody (Biotin)

abx431143-200ul 200 ul
EUR 384

Caveolin 1 (CAV1) Antibody

20-abx241052
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul

Caveolin 1 Protein (OVA)

20-abx165517
  • EUR 578.00
  • EUR 258.00
  • EUR 1720.00
  • EUR 690.00
  • EUR 425.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 (CAV1) Antibody

20-abx242330
  • EUR 411.00
  • EUR 300.00
  • 100 ul
  • 50 ul

Caveolin 1 (CAV1) Antibody

20-abx175748
  • EUR 1177.00
  • EUR 578.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx175750
  • EUR 425.00
  • EUR 133.00
  • EUR 1191.00
  • EUR 578.00
  • EUR 328.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Caveolin 1 (CAV1) Antibody

20-abx175751
  • EUR 1233.00
  • EUR 592.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx175752
  • EUR 1288.00
  • EUR 620.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx175753
  • EUR 1288.00
  • EUR 620.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx175754
  • EUR 1316.00
  • EUR 634.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx175755
  • EUR 1316.00
  • EUR 634.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx175756
  • EUR 1372.00
  • EUR 648.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx171646
  • EUR 787.00
  • EUR 411.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx171647
  • EUR 843.00
  • EUR 439.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx171648
  • EUR 843.00
  • EUR 439.00
  • 1 mg
  • 200 ug

Caveolin 1 (CAV1) Antibody

20-abx171649
  • EUR 871.00
  • EUR 453.00
  • 1 mg
  • 200 ug

Caveolin-1 (CAV1) Antibody

abx231313-100ug 100 ug
EUR 481

Caveolin-1 (CAV1) Antibody

abx231314-100ug 100 ug
EUR 481

Caveolin 1 (CAV1) Antibody

abx330500-100ul 100 ul
EUR 425

Caveolin 1 (CAV1) Antibody

abx332130-100ul 100 ul
EUR 425

Caveolin 1 (CAV1) Antibody

20-abx327354
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Caveolin 1 (CAV1) Antibody

20-abx328161
  • EUR 314.00
  • EUR 244.00
  • 100 ug
  • 50 ug

Anti-Caveolin 1 antibody

STJ70728 100 µg
EUR 359

Anti-Caveolin-1 antibody

STJ92050 200 µl
EUR 197
Description: Rabbit polyclonal to Caveolin-1.

Anti-Caveolin-1 antibody

STJ92051 200 µl
EUR 197
Description: Caveolin-1 is a protein encoded by the CAV1 gene which is approximately 20,4 kDa. Caveolin-1 is localised to the Golgi apparatus membrane and cell membrane. It is involved in eNOS activation and regulation, focal adhesion and lipoprotein metabolism. It is a scaffolding protein that makes up the main component of the caveolae plasma membranes found in most cell types. The protein links integrin subunits to the tyrosine kinase FYN which is an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression. Caveolin-1 is expressed in the brain. Mutations in the CAV1 gene may result in pulmonary hypertension and lipodystrophy. STJ92051 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of Caveolin-1 protein.

anti- Caveolin-1 antibody

FNab01313 100µg
EUR 505.25
Description: Antibody raised against Caveolin-1

anti- Caveolin-1 antibody

FNab01314 100µg
EUR 505.25
Description: Antibody raised against Caveolin-1

Caveolin-1 Polyclonal Antibody

40684-100ul 100ul
EUR 252

Caveolin-1 Polyclonal Antibody

40684-50ul 50ul
EUR 187

Recombinant human Caveolin-1

P1754 100ug Ask for price
Description: Recombinant protein for human Caveolin-1

Caveolin-1 Conjugated Antibody

C48674 100ul
EUR 397

Caveolin 1 Blocking Peptide

AF5372-BP 1mg
EUR 195

Caveolin-1 Blocking Peptide

AF6386-BP 1mg
EUR 195

Caveolin-1 Blocking Peptide

AF0126-BP 1mg
EUR 195

Anti-Caveolin-1 antibody

PAab01313 100 ug
EUR 355

Caveolin 1 antibody (Tyr14)

70R-35245 100 ug
EUR 327
Description: Purified Rabbit polyclonal Caveolin 1 antibody (Tyr14)

Caveolin antibody

10R-10553 100 ug
EUR 349
Description: Mouse monoclonal Caveolin antibody

OVA conjugated Caveolin 1 (CAV1)

4-CPA214Hu21
  • EUR 413.60
  • EUR 214.00
  • EUR 1276.00
  • EUR 492.00
  • EUR 884.00
  • EUR 340.00
  • EUR 3040.00
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Caveolin 1 expressed in: Protein conjugation

Anti-Caveolin-1/CAV1 Antibody

PA1514 100ug/vial
EUR 334

Moreover, genetic deletion of caveolin-1 or pharmacological blockade of Tie2 signaling successfully normalizes microvascular construction and barrier perform with attenuated EC-pericyte disassociation and CCM lesion formation in Pdcd10BECKO mice. Our examine establishes a persistent CCM mannequin and uncovers a mechanism by which CCM3 mutation-induced caveolae-Tie2 signaling contributes to CCM pathogenesis.